Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment.

Autor:	Ahmed, N., Kambhampati, S., Hamadani, M., Grover, N., Shadman, M., Locke, F. L., Gerson, J., Frank, M. J., Budde, L. E., Wang, M., Hu, Z., Nunes, A., Dalton, D., Kloos, I., Lee, D., Xu, H., Pasquini, M., Herrera, A.
Předmět:	MANTLE cell lymphoma SUBGROUP analysis (Experimental design)
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p488-490, 3p
Abstrakt:	This analysis included 272 pts (median follow-up, 6.6 mo; range, 0.3-16.5), excluding pts with prior non-HCT cellular therapy ( I n i = 7), missing data on prior treatment, or no follow-up. B Introduction: b Brexu-cel is a CAR T-cell therapy approved for adult patients (pts) with r/r MCL. Here, we describe real-world outcomes with brexu-cel analyzed by prior receipt of BTK inhibitor (BTKi), bendamustine, or autoHCT, and 1-2 versus >=3 prior lines (L) of therapy. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text